Herijgers N, Van Eck M, Groot P H, Hoogerbrugge P M, Van Berkel T J
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, Netherlands.
Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):1995-2003. doi: 10.1161/01.atv.17.10.1995.
The LDL receptor (LDLR) plays an important role in the removal of LDL and its precursors, the intermediate and very low density lipoproteins, from the blood circulation. The receptor is expressed on various cell types. In this study the relative importance of the LDLR on macrophages for lipoprotein metabolism and atherogenesis was assessed. For this purpose, irradiated LDLR-knockout (-/-) mice were transplanted with bone marrow of normal C57BL/6J mice. DNA analysis showed that the transplanted mice were chimeric. The transplantation resulted in a slight decrease of total serum cholesterol when compared with LDLR-/- mice that were transplanted with LDLR-/- bone marrow. This modest decrease, however, did not reach statistical significance at all time points examined. This decrease can be almost completely attributed to a decrease in LDL cholesterol. The specific lowering of LDL cholesterol could clearly be observed at 4 weeks after transplantation, but the decrease was less at 12 weeks after transplantation. Quantification of atherosclerotic lesions of mice fed a 1% cholesterol diet for 6 months revealed that there were no differences in mean lesion area between mice transplanted with wild-type bone marrow or LDLR-/- bone marrow. We anticipate that in LDLR-/- mice transplanted with wild-type bone marrow, the LDLR is downregulated by the relatively high concentrations of circulating cholesterol. In vitro incubations of peritoneal macrophages with 125I-LDL indicated that the LDLR of these cells could be downregulated by 25-hydroxycholesterol. Peritoneal macrophages isolated from LDLR-/- mice transplanted with wild-type bone marrow, in contrast to those transplanted with LDLR-/- bone marrow, were able to degrade 125I-LDL, indicating that the capacity to express functional LDLR was achieved. In conclusion, introduction of the LDLR into LDLR -/- mice via bone marrow transplantation resulted in only a relatively modest decrease of LDL cholesterol that became less pronounced at later time points, possibly due to downregulation of the LDLR. To utilize the LDLR in macrophages for effective cholesterol lowering, either the sterol-regulatory elements have to be "silenced" or a high-expression LDLR construct has to be introduced into macrophages, eg, via transplantation of in vitro transfected hematopoietic stem cells.
低密度脂蛋白受体(LDLR)在将低密度脂蛋白及其前体(中密度脂蛋白和极低密度脂蛋白)从血液循环中清除的过程中发挥着重要作用。该受体在多种细胞类型中表达。在本研究中,评估了巨噬细胞上的LDLR对脂蛋白代谢和动脉粥样硬化形成的相对重要性。为此,将经辐照的LDLR基因敲除(-/-)小鼠移植正常C57BL/6J小鼠的骨髓。DNA分析显示移植后的小鼠为嵌合体。与移植LDLR-/-骨髓的LDLR-/-小鼠相比,移植导致总血清胆固醇略有下降。然而,这种适度的下降在所有检测时间点均未达到统计学显著性。这种下降几乎完全归因于低密度脂蛋白胆固醇的降低。移植后4周可明显观察到低密度脂蛋白胆固醇的特异性降低,但移植后12周时降低幅度较小。对喂食1%胆固醇饮食6个月的小鼠的动脉粥样硬化病变进行定量分析发现,移植野生型骨髓或LDLR-/-骨髓的小鼠之间平均病变面积没有差异。我们推测,在移植野生型骨髓的LDLR-/-小鼠中,LDLR会被循环中相对较高浓度的胆固醇下调。用125I-LDL对腹腔巨噬细胞进行体外孵育表明,这些细胞的LDLR可被25-羟基胆固醇下调。与移植LDLR-/-骨髓的小鼠相比,从移植野生型骨髓的LDLR-/-小鼠中分离出的腹腔巨噬细胞能够降解125I-LDL,这表明获得了表达功能性LDLR的能力。总之,通过骨髓移植将LDLR引入LDLR-/-小鼠仅导致低密度脂蛋白胆固醇相对适度的下降,且在后期时间点这种下降变得不那么明显,这可能是由于LDLR的下调所致。为了利用巨噬细胞中的LDLR有效降低胆固醇,要么使固醇调节元件“沉默”,要么将高表达的LDLR构建体引入巨噬细胞,例如通过移植体外转染的造血干细胞。